Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2002

01-11-2002 | Original Article

Induction of cytotoxicity against autologous tumour cells by interleukin-12:evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients

Authors: Michael Ströhlein, Klaus-Uwe Grützner, Friedrich-Wilhelm Schildberg, Markus Heiss

Published in: Cancer Immunology, Immunotherapy | Issue 9/2002

Login to get access
Metadata
Title
Induction of cytotoxicity against autologous tumour cells by interleukin-12:evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients
Authors
Michael Ströhlein
Klaus-Uwe Grützner
Friedrich-Wilhelm Schildberg
Markus Heiss
Publication date
01-11-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0310-6

Other articles of this Issue 9/2002

Cancer Immunology, Immunotherapy 9/2002 Go to the issue

Original Article

Adhesion of lymphocytes to bladder cancer cells: the role of the αEβ7 integrin

Original Article

The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy

Original Article

Accumulation of CD45RO+ cells in peritoneal carcinomatous fluid favours survival of ovarian carcinoma patients

Original Article

Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28

Review

Neurotransmitters are regulators for the migration of tumor cells and leukocytes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits